Oncology
2 drugs are in development for Advanced Melanoma.
- Companies
- 2
- Clinical trials
- 15
BioSniper AIPage evidence connected
Prepared research question
Which programs lead the Advanced Melanoma pipeline—and what evidence could change the picture?
Run cited research
Traceable citations · Unknowns marked
Drug Pipeline by Phase
Approved(1)
| Drug | Company |
|---|---|
| COTELLIC (cobimetinib) | EXELIXIS, INC. (EXEL) |
Phase 2(1)
| Drug | Company |
|---|---|
| rp1 | Replimune Group, Inc. (REPL) |
About this indication
Advanced Melanoma context
Oncology·MeSH: Neoplasm Metastasis (D009362)
Narrower concept of MeSH descriptor Neoplasm Metastasis
Prevalence
75.0 / 100K
Incidence
23.0 / 100K/yr
Frequently asked questions
How many drugs are in development for Advanced Melanoma?
BioSniper tracks 2 drugs in development for Advanced Melanoma across 2 companies.
How many clinical trials target Advanced Melanoma?
There are 15 clinical trials targeting Advanced Melanoma tracked by BioSniper.
What is the prevalence of Advanced Melanoma?
The estimated prevalence of Advanced Melanoma is approximately 75.0 per 100,000 population.